XBIvsBBCETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. Virtus LifeSci Biotech Clinical Trials ETF (BBC) is part of the Tomorrow's Treatments segment. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, BBC's top sector exposures are Healthcare. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.65% for BBC. XBI is up 32.87% year-to-date (YTD) with +$966M in YTD flows. BBC performs better with 37.25% YTD performance, and +$5M in YTD flows. Run a side-by-side ETF comparison of XBI and BBC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs BBC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/08/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI BBC | +2.44%+1.24% | +26.14%+29.76% | +32.87%+37.25% | +72.26%+121.80% | +107.12%+158.10% | +23.20%+14.16% |
| Flows | XBI BBC | +$531M- | +$1.35B-$2M | +$966M+$5M | +$1.73B+$12M | +$26M+$16M | +$1.69B+$8M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI BBC | +29.80%+33.04% | +27.90%+35.99% | +28.27%+37.18% | +32.90%+39.59% |
| Max drawdown | XBI BBC | -10.46%-11.57% | -10.46%-14.64% | -32.94%-54.25% | -53.28%-70.43% |
| Max drawdown duration | XBI BBC | 40d40d | 40d60d | 331d340d | 1622d1666d |
Trading data
XBI | BBC | |
Last sale 9/9/2026 at 3:22 PM | $160.28 | $53.28 |
| Previous close 09/08/2026 | $161.93 | $53.71 |
| Consolidated volume 09/08/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | BBC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/9/2026 at 3:22 PM
Live
Closed
XBI | BBC | |
|---|---|---|
| Last price | $160.28 | $53.28 |
| 1D performance | -1.02% | -0.80% |
| AuM | $11.33 B | $50.44 M |
| E/R | 0.35% | 0.65% |
Characteristics
XBI | BBC | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | VIRTUS Investment Partners |
| Benchmark | S&P Biotechnology Select Industry Index | LifeSci Biotechnology Clinical Trials Index |
| N° of holdings | 149 | 127 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
BBC
USA
86.49%
Other
13.51%
Sectors
XBI
Healthcare
99.41%
Other
0.59%
BBC
Healthcare
95.06%
Other
4.94%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
BBC
Total weight of top 15 holdings out of 15
15.32%
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
BBC
First Tracks Biotherapeutics, Inc.
1.57%
Monopar Therapeutics, Inc.
1.22%
MBX Biosciences, Inc.
1.14%
Zenas BioPharma, Inc.
1.09%
Xencor, Inc.
1.06%
Apogee Therapeutics, Inc.
1.00%
REGENXBIO, Inc.
0.96%
Oric Pharmaceuticals, Inc.
0.96%
Dyne Therapeutics, Inc.
0.93%
uniQure NV
0.91%
SELLAS Life Sciences Group, Inc.
0.91%
Nurix Therapeutics, Inc.
0.91%
Vor Biopharma, Inc.
0.89%
Erasca, Inc.
0.89%
Amylyx Pharmaceuticals, Inc.
0.88%
Frequently asked questions about XBI and BBC
How have the XBI and BBC ETFs performed in 2026?
As of September 8, 2026, XBI is up 32.87% year-to-date (YTD), while BBC has returned 37.25%. That puts BBC better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or BBC?
Year-to-date, the XBI ETF saw +$966M in flows, compared to +$5M for BBC.
Which ETF is more volatile: XBI or BBC?
Over the past year, XBI had a volatility of 27.9%, while BBC experienced 35.99%.
Which ETF is bigger: XBI or BBC?
As of September 8, 2026, XBI holds $11.33 B in assets under management (AUM), while BBC manages $50.44 M.
What sectors do the XBI and BBC ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, BBC focuses on Healthcare.
What are the top holdings of the XBI ETF and BBC ETF?
XBI top holdings include Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc.. BBC holds in its top three: First Tracks Biotherapeutics, Inc., Monopar Therapeutics, Inc. and MBX Biosciences, Inc..
Which ETF is more diversified: XBI or BBC?
XBI holds 151 securities with 20.29% of its assets in the top 15. BBC has 127 securities and a top 15 weight of 15.32%.
Advertisement
Latest news about XBI & BBC
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
BBC
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
